Monte Rosa Therapeutics Inc (GLUE) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.39x

Monte Rosa Therapeutics Inc (GLUE) has a Cash Flow Reinvestment Rate of 0.39x as of September 2025, reinvesting $38.79 Million (capex $651.00K plus investments $38.14 Million) from operating cash flow of $100.43 Million. Check Monte Rosa Therapeutics Inc (GLUE) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.39x
(Capex + Investments) / Operating CF

Total Reinvested

$38.79 Million
Capex + Investments

Operating Cash Flow

$100.43 Million
USD

Capital Expenditures

$651.00K
USD

Monte Rosa Therapeutics Inc Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for Monte Rosa Therapeutics Inc across 1 annual periods. Explore GLUE debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Monte Rosa Therapeutics Inc (2024–2024)

Year-by-year capital reinvestment analysis for Monte Rosa Therapeutics Inc. For live market cap and broader valuation context, see Monte Rosa Therapeutics Inc stock valuation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.15x $48.44 Million $42.00 Million $3.99 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow